Cis-dichlorodiammineplatinum (II) and VP 16–213 combination chemotherapy for non-small cell lung cancer

✍ Scribed by Goldhirsch, Aron ;Joss, Rudolf A. ;Cavalli, Franco ;Sonntag, Roland W. ;Brunner, Kurt W.

• Publisher: John Wiley and Sons
• Year: 1981
• Tongue: English
• Weight: 230 KB
• Volume: 9
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950090302

✦ Synopsis

Abstract

Twenty‐three patients with non‐small cell lung cancer were treated with a combination of cis‐dichlorodiammineplatinum(II) 100 mg/m^2^ IV on day 1 and VP 16–213 80 mg/m^2^ IV on days 1–3. Eighteen patients are evaluable for response. Seven partial remissions with a median duration of 3 months (range, 1–13+) have been observed. Three patients exhibit stable disease, and eight patients show tumor progression. Overall survival was 5+ months (range, 1–13+); 7.5 months (range, 3–13+) for responders and 3+ months (range, 1–9+) for non‐responders. Hematologic toxicity was acceptable, but poor subjective tolerance (nausea, vomiting, loss of appetite) was the main factor limiting treatment duration.